CClinicalTrials.gg
CompletedNCT05917236BAUpdated Jun 23, 2023

Biliary Atresia With Rare Associations, a Case Report

An observational study in BA - Biliary Atresia, sponsored by Sarah Magdy Abdelmohsen. Completed at 1 site in Egypt. Open to female participants aged 2 Months to 3 Months. Per ClinicalTrials.gov, last updated 2023-06-23.

Sponsored by Sarah Magdy Abdelmohsen · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
1
Ages
2 Months to 3 Months
Sex
Female
01

Study summary

Background: It is not often written in medical journals that preduodenal portal vein, biliary atresia, intestinal malrotation, and situs inversus totalis are all related.

Case reports: A two-month-old female infant had biliary atresia type III, situs inversus totalis, midgut malrotation, and preduodenal portal vein. She had been operated on by the Kasai procedure (hepato-portoenterostomy).

Discussion: It is important to carefully look into the relationship between preduodenal portal vein and biliary atresia because the patient at a risk of injury from this aberrant vein at operative intervention.

Read the detailed description

A full-term female infant, G1P1, weighing 3450 g at birth, was referred to our department at the age of 2 months old with severe jaundice and poor feeding. The mother reported yellow sclera and skin, lightning-colored stool, and dark colored urine a few days after birth, which were progressively aggravated.

On physical examination, the infant had an olive-green colored sclera and skin with an itching mark, a pale clay stool in the diaper, a law grade fever of 37.8°C, a weight of 3870 g, a pulse rate of 138 b/m, and a respiratory rate of 38 b/m. The heart sounds and breath sounds were normal. The abdomen was soft and lax on examination. The liver was two fingers below the costal margin. The intestinal sound was normal.

The laboratory investigation revealed that total bilirubin was elevated at 7 mg/dl, direct bilirubin was elevated at 4 mg/dl, GGT was elevated at 157,1 U/L, alkaline phosphatase was elevated at 279 U/L, and albumin was decreased at 3.4 g/dL.

Abdominal ultrasonography revealed a triangular cord sign in the liver hilum, an absent gall bladder, and a normal-sized spleen on the right side behind the liver. A chest x-ray revealed dextrocardia. The HIDA scan revealed failure of radioisotope excretion in the duodenum . Non-contrast magnetic resonance cholangiopancreatography (MRCP) showed that the common hepatic duct and the common bile duct could not be seen. Preoperative percutaneous liver biopsy reported liver fibrosis, bile ductules proliferation and cholestasis.

An experienced pediatric surgeon obtained the decision for exploratory laparotomy by right subcostal abdominal incision. The spleen is located in the right upper quadrant behind the liver. Extracorporealization of the liver is done . The gall bladder was rudimentary. On further exploration, the principle investigator also found intestinal malrotation (IM) and PDPV. All extrahepatic bile ducts were absent; type III portal atresia. The portal palate was dissected easily and the rudimentary gall bladder was removed.

Widening of the narrow base of the intestinal mesentery, then reconstruction of the retro-colic Roux-en-Y limb of the jejunum, and finally hepato-portoentostomy (Kasai operation) was done . A wedge liver biopsy obtained reported ductular proliferation, hepatic fibrosis, and bile plugs; a feature suggestive of biliary obstruction.

The post-operative follow-up of the patient revealed features of bile drainage in the intestine; the stool returned to its normal brawn color; and the yellow skin color was slightly improved. Total bilirubin was 4 mg/dl and direct bilirubin was 2 mg/dl. The patient was discharged on the tenth post-operative day.

02

Conditions studied

  • BA - Biliary Atresia

Browse trials for

03

In context

Biliary Atresia

75 studies on the registry are indexed under Biliary Atresia; 25 are open to participants now.

This study's enrollment of 1 is below the median of 126 across 31 observational studies indexed under Biliary Atresia.

Browse Biliary Atresia studies →

Lead sponsor

Sarah Magdy Abdelmohsen is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Months to 3 Months
Sexes eligible
Female
Sampling method
Non-probability sample

Study population

one case reports

Inclusion criteria

  • Biliary atresia with another syndrome

Exclusion criteria

Exclusion Criteria:

  • Biliary atresia alone
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
1 participant (actual)
Target follow-up
1 Year
Patient registry
Yes

Interventions

  • Procedurehepato-portoentostomy

    the retro-colic Roux-en-Y limb of the jejunum, and finally hepato-portoentostomy (Kasai operation)

    Also known as: (Kasai operation)

06

What researchers measure

Primary outcomes

  1. Is the infant will still a live or he will dies?

    Is the infant will continue his life up to one year or he will dies during the follow-up period.

    Time frame: from 3 weeks to one year follow up

07

Study locations

1 site
  • Aswan university
    Aswan, Sahary 81528, Egypt
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05917236
Lead sponsor
Sarah Magdy Abdelmohsen
Responsible party
Sarah Magdy Abdelmohsen (Principal Investigator, Aswan University Hospital) — Sponsor-investigator
First posted
Jun 23, 2023
Start date
Sep 1, 2021
Primary completion
Sep 1, 2021
Completion
Sep 1, 2022
Last update
Jun 23, 2023

Study contacts

Sarah M Abdelmohsen, Lecturer
study director · Aswan University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion